Last edition
News about "Australian biotechnology company Immutep"
Dr. Reddy's Signs USD 370 Million Licensing Deal for Eftilagimod Alfa
Dr. Reddy’s Laboratories has entered into an exclusive licensing agreement with Australian biotechnology company Immutep to commercialise its investigational immunotherapy, Eftilagimod Alfa (Efti), across markets outside North America, Europe, Japan and Greater China.
Australian Biotechnology Company Immutep | 09/12/2025 | By Darshana | 123
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members